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Abstract
Background: Aortic aneurysms and/or dissection (AADs) in the aorta are a leading cause of human morbidity and
mortality. To date, data on non-syndromic thoracic AADs (TAADs) have been mainly derived from Caucasians, and
the genetic basis of TAADs remains to be elucidated. In this study, we assessed gene mutations in a Chinese
population with TAADs.
Methods: A cohort of 68 non-syndromic familial TAAD Chinese patients was screened for the most common TAAD-
causing genes (ACTA2, MYH11, TGFBR1, TGFBR2, and SMAD3) using high-resolution melting (HRM) analysis. Thereafter,
142 unrelated non-syndromic sporadic cases were recruited and further analyzed using HRM analysis to estimate the
prevalence of disease-causing mutations in these candidate genes.
Results: Two novel ACTA2 mutations (N117I and L348R) were identified in each familial TAAD proband separately, and
an additional novel ACTA2 mutation (Y168N) was identified in one patient with sporadic TAADs. In contrast, none of the
three mutations occurred in 480 control subjects. Also, no other gene mutations were identified in this cohort of Chinese
TAAD patients.
Conclusions: The current study identified three novel ACTA2 mutations in Chinese TAAD patients, and these mutations
represented the most predominant genes responsible for non-syndromic TAADs. In addition, HRM analysis was shown
to be a sensitive and high-throughput method for screening gene mutations.
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Background
Aortic aneurysms and/or dissections (AADs) are a group of
common vascular disorders characterized by cardiovascular
manifestations, which include aortic dilatation, aneurysms,
and dissection. AADs are the most common and life-
threatening disorder in humans, and aortic aneurysms usu-
ally result from accumulated degenerative changes and tend
to be asymptomatic until sudden dissection or rupture oc-
curs. Therefore, the immediate mortality rate is as high as
1 %–2 %, and related medical expenditures are high. Thus,
early diagnosis, prevention of sudden dissection or rupture,
and treatment are critical to improve patient survival. The
etiology of thoracic ADDs (TAADs) is complex and hetero-
geneous, and previous studies clearly showed that genetic
factors contribute to the risk of the disease [1–8] in
addition to environmental risk factors, such as tobacco
smoking and gender or other diseases, e.g., hypertension
and atherosclerosis, which also influence or modify the risk
[1]. Furthermore, TAADs can occur in patients with con-
nective tissue diseases, such as Marfan syndrome (MFS),
Loeys-Dietz syndrome (LDS), and Ehlers-Danlos syndrome
(EDS). A TAAD may also manifest as an isolated disease,
and the majority of the non-syndromic patients have spor-
adic episodes. Only approximately 20 % of cases were
inherited in a Mendelian fashion. The primary model of in-
heritance is autosomal dominant with reduced penetrance
and variable expression [1, 2]. The genetic basis for non-
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syndromic TAADs has recently been a focus of research.
Among the identified genes, ACTA2 (localized at chromo-
somal 10q23-24) encodes a smooth muscle cell (SMC)-spe-
cific isoform of the contractile protein α-actin, which is the
most important candidate pathogenic gene. ACTA2 muta-
tions are responsible for approximately 10 %–15 % of famil-
ial TAAD cases and nearly 2 %–4 % sporadic cases [3, 4].
Moreover, TGFBR1 mutations (localized at chromosome
9q33-34) account for up to 2 % of cases, and TGFBR2
mutations (localized at chromosome 3p24-25) account for
up to 3 % of cases. MYH11 mutations (localized at
chromosome 16p12-13) account for 1 %–2 % of cases,
and other gene mutations (FBN1, SMAD3, TGFB2,
MYLK, PRKG, MFAP5, and MAT2A) have also been
reported previously [5–8].
However, to date, data on non-syndromatic TAADs have
been mainly derived from Caucasian populations, and
mutations in these genes in Chinese TAAD patients have
not been assessed so far [9, 10]. Molecular or genetic stud-
ies of TAADs could provide an insight into the mechanism
underlying the pathogenesis of TAADs and benefit the de-
velopment of novel strategies for early diagnosis and clinical
management or prevention of sudden dissection or rupture.
Toward this end, our current study analyzed the most com-
mon TAAD-causing genes (ACTA2, MYH11, TGFBR1,
TGFBR2, and SMAD3) in 68 Chinese non-syndromic fa-
milial TAAD patients using high-resolution melting (HRM)
analysis. We then confirmed the prevalence of ACTA2
mutations in 142 unrelated cases of sporadic TAADs. The
high numbers of genes and their mutations in TAADs have
made the molecular characterization of this disease tech-
nically challenging. HRM analysis has been proven to be a
rapid and powerful molecular biology technique for de-
tecting genetic variations in double-stranded DNA sam-
ples [11]. Our current study utilized HRM analysis to
systemically screen and identify gene mutations in a cohort
of Chinese patients with non-syndromatic TAADs.
Methods
Study population
Patients and controls were identified and enrolled from
several local medical centers in the central region of China.
All patients received systemic medical assessment, and de-
finitive diagnosis of TAADs was made on the basis of com-
puted tomography (CT) angiography and echocardiogram.
We carefully investigated specific clinical features in each
patient, and the characteristics of connective tissue disor-
ders were also identified. We excluded patients with any
skeletal, muscular, dermal, or ocular defects; thus, patients
with syndromic TAADs were excluded from this study.
Clinicopathological data (age, gender, and other relevant
medical data) were obtained from patients’ medical records
and are summarized in Table 1.
DNA extraction and gene mutation analysis
A venous blood sample (3–5 ml) from each participant was
collected, and genomic DNA was extracted using the DNA
Isolation Kit for Mammalian Blood (Roche Diagnostics Co.,
Indianapolis, IN, USA) according to the manufacturer’s
protocol. After quantification, the DNA samples were sub-
jected to HRM analysis. The polymerase chain reaction
(PCR) primers were designed using online Primer 3 soft-
ware to flank the coding regions of five genes (TGFBR1,
TGFBR2, ACTA2, MYH11, and SMAD3), and the amplicon
size ranged between 100 and 250 bp in length. Their map
locations were verified with UCSC In-Silico PCR. Prior to
HRM analysis, PCR with control samples was carried out
to test the specificity of these primers (Table 2). Additional
primer information is available upon request.
PCR amplification was achieved in 25 μL of a PCR
mixture containing 1.5 mmol/L Mg2+, 0.2 mmol/L dNTPs,
0.2 μmol/L of each primer, 25 ng genomic DNA, 5 μmol/L
SYTO 9 green fluorescent (Invitrogen, Carlsbad, CA,
USA), and 0.2 U Taq DNA polymerase (Tiangen, Beijing,
China) and performed on an ABI 9700 System (Applied
Biosystems, Foster City, CA, USA) with a thermal profile
of 95 °C for 5 min, 40 cycles of 95 °C for 10 s, appropriate
annealing temperatures for 10 s, and 72 °C for 15 s, and
then a final extension at 72 °C for 10 min. PCR products
were then directly screened using HRM analysis on a
Rotor Gene 6000 System (Corbett Life Science, Sydney,
Australia) using standard protocols with minor modifica-
tions. The optimized melting temperatures used to analyze
PCR amplicons are listed in Table 2. Fluorescence data
were visualized and analyzed by the Rotor Gene scan-
ning software, and the melt curves were normalized
Table 1 Clinicopathological characteristics of TAAD patients
Clinical data Number of patients (%)











Thoracic AAD 45 (21.4)
Thoracic and abdominal AAD 165 (78.6)
Note: Thoracic AAD includes thoracic aortic dissection, thoracic aortic
aneurysm, and ascending aortic aneurysmal dilatation; abdominal AAD
includes abdominal aortic dissection and abdominal aortic aneurysm; thoracic
and abdominal AAD includes thoracic and abdominal aortic dissection and
thoracic and abdominal aortic aneurysm
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and subsequently analyzed manually. Significant differ-
ences in the fluorescence signal from the horizontal
baseline were indicative of DNA variations.
To validate the HRM results, we reanalyzed all of the
samples that yielded atypical curves using conventional
Sanger sequencing. DNA sequence analysis was performed
using the BigDye Terminator Cycle Sequencing v3.1 kit on
an ABI 3100 genetic analyzer (Applied Biosystems) as de-
scribed previously [12].
Bioinformatic analysis
To assess the deleterious effect of identified sequence
variants, we used various online amino-acid substitution
prediction programs, including SIFT (http://sift.jcvi.org),
PolyPhen2 (http://genetics.bwh.harvard.edu/pph2), and
Mutation taster (http://mutationtaster.org/) to predict
whether a variant is likely to affect protein coding and
functions. We then analyzed the potential effects of the
mutated nucleotides on messenger RNA splicing using
NetGene2 (www.cbs.dtu.dk/services/NetGene2/).
Statistical analysis
All statistical analyses were performed using SPSS (version
17.0; SPSS, Inc., Chicago, IL, USA). A two-tailed P value
<0.05 was considered statistically significant.
Results
Characteristics of the study population
In this study, we enrolled a total of 290 participants for
complete clinical evaluation of TAADs and diagnosed
210 of them with unrelated non-syndromic TAADs. The
mean patient age was 48.9 ± 10.8 years (range, 17–93
years), and the study population included 174 (82.9 %)
men and 36 (17.1 %) women (nearly a 4.8:1 male to fe-
male ratio). The age at onset of TAADs did not differ
significantly (p > 0.05) between genders, and 68 (32.4 %)
cases had a family history of TAADs (Table 1).
Gene mutations in TAAD patients
Sixty-eight probands with familial non-syndromatic TAADs
were systematically screened for mutations of the common
TAAD-causing genes (MYH11, ACTA2, TGFBR1, TGFBR2
and SMAD3) using HRM analysis. We did not find any
mutations in these four genes except ACTA2, and two
probands (2.9 %) had a novel heterozygous missense muta-
tion in the coding region of ACTA2, respectively, i.e., muta-
tion c.825A >T (p.N117I) within exon 4 and mutation
c.977 T >A (p.Y168N) within exon 6 (Fig. 1a).
We further assessed and confirmed the prevalence of
disease-causing mutations of the MYH11, ACTA2, TGFBR1,
TGFBR2, and SMAD3 genes in 142 Chinese, unrelated non-
syndromic sporadic TAAD patients and identified only one
novel heterozygous missense mutation in one patient [1/
142, 0.7 %; c.1518 T >G (L348R)] in exon 9 of the ACTA2
gene (Fig. 1a). In contrast, no mutations within these genes
were identified in the 480 healthy control individuals.
All of these three ACTA2 mutations are absent from the
dbSNP (http://www.ncbi.nlm.nih.gov/SNP), 1000 Genomes
(www.1000genomes.org), and the NHLBI Exome Sequen-
cing Project databases (http://evs.gs.washington.edu/EVS),
indicating that they are novel ACTA2mutations.
In silico prediction of the deleterious effects of the three
identified mutations
The structure of ACTA2 is available from the Protein
database, and the mutated residues identified are mapped
on the 3D protein structure. The N117 residue is found in
an α-helix, whereas the Y168 residue is located outside of
the regular secondary structures. The L348 residue is lo-
calized in the interior of a helix in this model (data not
shown). All three mutations occurred in evolutionarily,
highly conserved amino acid residues (Fig. 1b).
Furthermore, we evaluated the potential consequences
in terms of altered protein function for each missense
mutation using SIFT, PolyPhen-2, and Mutation taster
Table 2 PCR primers and HRM conditions for scanning mutations of the entire ACTA2 coding region
Exon Forward primer Reverse Primer Size (bp) PCR Tm (°C) HRM Tm (°C)
Exon 2 5'-tgcccaattacagctgaggct-3' 5'-tctgtgtcctgttatgttccaatca-3' 233 58 82-87
Exon 3 5'-tttgggagatgctgactcataatgtg-3' 5'-tgcatcctgagggcccaagct-3' 208 58 80-85
Exon 4 5'-catcattgtgtttctcctctgtcc-3' 5'-gaagtttccccagaccccacag-3' 197 58 82-87
Exon 5 5'-tttgtcagatgggcaccttca-3' 5'-gcgctccaaccagcttgctgtc-3' 173 58 82-87
Exon 6 5'-ccagctgccatggtgacttatc-3' 5'-cccctctcccccttatctccca-3' 235 58 82-87
Exon 7-1 5'-cacctgtgcagaccctaatgtttg-3' 5'-ggtctctgggcagcggaaac-3' 220 58 80-85
Exon 7-2 5'-ccactgccgcatcctcatcct-3' 5'-agacaatgactccccttcccag-3' 164 58 82-87
Exon 8-1 5'-acttaaggaccatggcctgtgtc-3' 5'-atcttcatggtgctgggtgctag-3' 211 58 80-85
Exon 8-2 5'-aatgtcctatcagggggcacca-3' 5'-gctgacactgctggcggc-3' 144 58 82-87
Exon 9-1 5'-ctgcactaatgatgacattaatgacc-3' 5'-ggagcaggaaagtgttttagaag-3' 210 58 82-87
Exon 9-2 5'-cgggccttccattgtccac-3' 5'-aatggtatcagtcgagtattgatcg-3' 225 58 80-85
Note: Several pairs of primers were synthesized for PCR amplification of exons 7, 8 and 9
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software and found that all three mutations were likely
deleterious: N117I (SIFT: affect protein function; Poly-
phen2: possibly damaging; Mutation taster: disease caus-
ing), Y168N (SIFT: affect protein function; Polyphen2:
probably damaging; Mutation taster: disease causing),
and L348R (SIFT: affect protein function; Polyphen2:
possibly damaging; Mutation taster: disease causing).
Taken together, our data provide strong genetic evidence
Fig. 1 Identification of three novel ACTA2 mutations in Chinese TAAD patients. a DNA sequencing data for normal controls and patients.
b Evolutionary conservation of the ACTA2 protein sequences involving and surrounding the three mutations identified in this study. All three
affected residues have been highly conserved during evolution
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that these mutations are likely pathogenic mutations in
the development of TAADs.
Clinical features of mutation-positive patients
The clinical features of the patients carrying an ACTA2
mutation are summarized in Table 3.
Patient 1 and family
A 39-year-old male proband presented with acute chest
pain. His medical history included 8 years of hypertension
and a type A dissection originating from the aortic root and
stretching to the abdominal aorta. The primary entry was
located on the aortic sinotubular junction. The maximal
diameter of the ascending aorta was 6.0 cm, and some
small ruptures were found on the aortic arch and descend-
ing aorta. At 27 h after hospital admission, the patient
underwent emergency surgery of the Bentall procedure
with total arch replacement and a frozen elephant trunk.
His recovery was uneventful. A missense mutation N117I
was detected in this proband, and this mutation occurred
in the affected patient’s father also and not in other family
members (Fig. 2).
Patient 2 and family
A 38-year-old male proband was diagnosed with an acute
type B dissection. CT angiography showed that the dissec-
tion originated from the ostia of the left subclavian artery
(LSA) and stretched to the right common iliac artery. The
primary entry was located on the lesser curvature of the
descending aortic arch. The bilateral renal arteries, celiac
trunk, and superior mesenteric artery were supplied by
the true lumen of the abdominal aorta. The patient under-
went endovascular repair with a covered-stent graft from
Medtronic (30 × 160 mm) without any complications. The
mutation L348R was identified in this TAAD patient, his
affected mother, and his unaffected son, but not in other
family members who underwent genetic testing (Fig. 2
and Table 3).
Patient 3 and family
A 31-year-old male patient was admitted to the clinic for
assessment of the cause of a cardiac murmur after birth
and intermittent dizziness for 3 years. Routine ultrasonic
cardiogram revealed a bicuspid aortic valve with severe
stenosis and aneurysmal dilatation of the ascending aorta.
CT angiography showed that maximal diameter of the
ascending aorta was 5.7 cm, and the three main branches
of the aortic arch were normal. The patient underwent a
successful Bentall surgery. A missense mutation Y168N
was identified in this patient, but this mutation was absent
in both parents. The paternal relationship was confirmed
by genotyping and linkage analysis of five highly poly-
morphic microsatellite markers (data not shown). These
results indicate that the Y168N mutation is a de novo mu-
tation (Fig. 2 and Table 3).
Discussion
Multiple genetic causes of non-syndromic TAADs have
been evaluated and identified in patients from Europe,
North America, and Japan, but little is known about such
causes in Chinese TAAD patients. In the current study,
we examined 210 Chinese patients with non-syndromic
Table 3 Characteristics of individuals with ACTA2 mutations
Family patient Age (y)/sex Exon Nucleotide Amino acid change Inheritance Clinical characteristics
change (GRCh37/hg19)
Family 1
I:1 44/male 4 chr10:90703573 T > A p.N117I Familial TAAD, stroke
cDNA.825A > T
II:1 39/male 4 chr10:90703573 T > A P.N117I Familial TAAD, AAAD,hypertension,
cDNA.825A > T
Family 2
I:2 56/female 6 chr10:90695071A > C p.L348R Familial TAAD
cDNA.1518 T > G
II:1 38/male 6 chr10:90695071A > C p.L348R Familial TAAD, AAAD
cDNA.1518 T > G
III:1 12/male 6 chr10:90695071A > C p.L348R Familial no symptom
cDNA.1518 T > G
Family 3
II:1 31/male 9 chr10:90701100A > T p.Y168N De novo TAAD,BAV, AS
cDNA.977 T > A
TAAD thoracic aortic aneurysms and/or dissection, AAAD abdominal aortic aneurysms and/or dissection, BAV bicuspid aortic valve, AS aortic stenosis. Roman
numerals indicate the generation (I, II or III) and Arabic numbers (1, 2, or 3) indicate the birth order of siblings
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TAADs by screening for mutations in the most frequent
TAAD-causing genes, but we failed to detect the muta-
tions of MYH11, TGFBR1, TGFBR2, and SMAD3. We did
successfully identify three de novo ACTA2 mutations in
our cohort of patients. The data provide direct evidence
that mutations of ACTA2 are likely the major cause of
non-syndromic TAADs in Chinese patients.
Because the molecular mechanisms of TAAD develop-
ment involve multiple genetic factors, molecular analysis
of TAAD patients is challenging. Whole exome sequen-
cing is indeed increasingly being used to investigate the
genetic basis of TAADs [13, 14], but to date, most of the
mutational screening in patients has been performed by
direct DNA sequencing. However, both conventional
method for large-scale detection of mutations and whole
exome sequencing are expensive and technically time-
consuming. Thus, HRM analysis has been successfully
used to overcome these limitations and constitutes a
detection method with a nearly 100 % detection accur-
acy [15]. In our current study, we developed a fast gen-
etic HRM screening strategy to identify gene mutations
in TAAD patients, and to the best of knowledge, this is
the first study to apply HRM technology for scanning
TAAD-associated genes in a large cohort of patients.
Our results demonstrate that HRM is a sensitive and
high-throughput method for the identification of TAAD-
causing mutations.
Thus, our current study was able to detect ACT2A2
mutations in 2.9 % (2/68) of familial cases and 0.7 % (1/
142) of sporadic cases, rates which are significantly lower
than those previously reported for ACTA2 mutations in
North America, Europe, and Japan (approximately 10 %–
15 % of familial TAAD cases and 2 %–4 % of sporadic
cases) [3–21]. There are three possible reasons for these
discrepancies. First, these differences may be due to un-
identified ACTA2 mutations within noncoding regulatory
sequences of ACTA2 or the intron region or the presence
of large insertion/deletions of ACTA2 locus that may con-
tribute to TAAD risk. Secondly, it is possible that the preva-
lence of ACTA2 mutations in the Chinese population was
underestimated due to our limited sample size. Thirdly, the
differences in the detection rate of TAAD-causing muta-
tions in ACTA2 may be racially related. For example, it has
been reported that the frequency of causal mutations or
genomic variants (i.e., population-specific single nucleotide
polymorphism) in some cardiovascular diseases, such as
hypertrophic cardiomyopathy, long QT syndrome and
coronary artery disease, are obviously different between
Caucasian and Chinese populations [22–24]. In addition,
although previous studies identified a higher rate of ACTA2
mutations, the cohorts may have been selected through a
special medical or genetic program in those studies.
Similar to the findings in our study, Bee et al. reported
a significantly lower rate of ACTA2 mutation (3 %) in
100 probands [20].
Since the first TAAD-causing ACTA2 mutation was
identified in 2007, more than 20 different ACTA2 muta-
tions have been identified and are scattered throughout
the whole coding region of ACTA2 [3, 4, 16–21]. Specific
ACTA2 mutations are associated with particular forms of
Fig. 2 Pedigree of Chinese families with ACTA2 mutations. Affected males and females are indicated by filled squares and circles, respectively, and
normal individuals are shown as open symbols. Arrow: the proband, +: mutation present, −: mutation absent. Roman numerals indicate the generation
(I, II or III) and Arabic numbers (1, 2, or 3) indicate the birth order of siblings
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vascular involvement. In our current study, we found
three novel ACTA2 mutations, and the 117-arginine resi-
due was affected by mutation of the threonine residue
identified previously [16]. Thus, our current data suggest
that Arg117 can also be mutated to an isoleucine residue.
Notably, although the clinical manifestations of patients
(I:1 and II:1) with the ACTA2 R117I mutation in family 1
are variable, a TAAD was the first and only symptom that
has been presented by this proband, whereas another mu-
tation carrier (I:1) had a stroke that occurred in middle-
age and the proceeded to have a TAAD. Although genetic
alteration has been previously reported at the location
R117, stroke was found to occur in Caucasian individuals
with the p.R117T mutation [16]. We observed stroke in
the setting of the mutation altering R117 in our Chinese
population as well, and this finding further supports that
ACTA2 mutation may be responsible for stroke in TAAD
patients. However, to date, although the genotype–pheno-
type correlation has not been fully documented for
ACTA2-related TAADs, it is suggested that the majority of
aortic aneurysms or dilatation in patients with an ACTA2
mutation may result in dissections at diameters below clas-
sic surgical thresholds (aortic root diameter <50 mm) [17].
In our current study, the aortic diameter of proband II:1
(family 1) was 6.0 cm at the time of dissection. In family 3,
the patient II:1 had a maximal ascending aortic diameter of
5.7 cm, and aortic aneurysmal dilatation was associated
with bicuspid aortic valve and aortic stenosis. All these
inter- and intra-family phenotypic variations may suggest
environmental or genetic factors play important roles in the
development of TAADs and ACTA2-associated vascular
diseases.
The molecular consequences of the three identified novel
ACTA2 mutations are still unknown, and most ACTA2
mutations identified so far are missense mutations, which
act via a dominant negative mechanism. Thus, we speculate
that these three novel mutations may act similarly to other
heterozygous ACTA2 mutations, and such substitutions
may disrupt actin filament assembly or stability, impair
contraction of SMCs, lead to vascular remodeling, and
ultimately contribute to an increased aneurysm and dissec-
tion susceptibility [3, 25]. Furthermore, recently, enhanced
transforming growth factor beta (TGF-β) signaling with
downstream canonical pSmad2 upregulation has been
described in TAADs, and regulation of TGF-β signaling
and SMC function and proliferation are all involved in the
pathogenesis of TAADs [21]. Thus, further studies are
needed to better understand the pathogenesis of TAADs in
Chinese patients.
Our current study has several potential limitations. For
example, we analyzed only ACTA2, MYH11, TGFBR1,
TGFBR2, and SMAD3 in the familial and sporadic TAAD
cases, but not other genes, such as FBN1, SMAD3,TGFB2,
MYLK, PRKG, MFAP5, andMAT2A, which may be altered
(although potentially less frequently) in non-syndromic
TAAD in the Chinese population. Furthermore, our study
lacked in vitro functional confirmation tests to illustrate
the functional changes resulting from this gene mutation,
and thus, further research is needed to better understand
the pathogenesis of non-syndromic TAAD.
Conclusion
In conclusion, the current study evaluated ACTA2 muta-
tions in Chinese TAAD patients and identified three novel
ACTA2 mutations that may have contributed to the devel-
opment of TAADs in these patients. Thus, detection of
ACTA2 mutations could be useful for molecular diagnosis
and genetic counseling for Chinese TAAD patients. More-
over, the current study demonstrated that HRM is a useful
and high-throughput technique for detecting gene muta-
tions in clinical samples.
Highlights
 HRM analysis is a useful technique for screening
gene mutations in TAAD patients.
 Three novel ACTA2 mutations were identified in
Chinese non-syndromatic TAAD patients.
 Racial/ethnic traits may explain the low rate of
ACTA2 mutations in Chinese patients.
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